Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00108095 · ClinicalTrials.gov registry record · Phase 2
A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 701
- Enrollment target
NCT00108095 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 701 participants.
The verdict
NCT00108095, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 701 participants
- Enrollment target
Study Summary
This study is looking at a range of doses of this NK-1 receptor antagonist drug, for both safety and effectiveness in prevention PONV
Interventions
- DRUG intravenous ondansetron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 701 participants |
| Start Date | 2004-10 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00108095
The ClinicalTrials.gov registry entry for NCT00108095 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 701 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which intravenous ondansetron is the first listed.
NCT00108095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00108095 about?
NCT00108095 is a clinical study titled "A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting". This study is looking at a range of doses of this NK-1 receptor antagonist drug, for both safety and effectiveness in prevention PONV
What is the current status of trial NCT00108095?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 701 participants. The study started on 2004-10. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00108095?
The interventions under investigation include: intravenous ondansetron (DRUG).
Who is sponsoring clinical trial NCT00108095?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.